Download Free Medical Non-Hodgkins Lymphoma PowerPoint Presentation

Non-Hodgkins Lymphoma PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation on cancer titled "Non-Hodgkin’s Lymphoma" provides information on Non-Hodgkin’s lymphomas (NHL), a heterogeneous group of malignant lymphomas and its different subtypes. The presentation also tells how morphology, immunophenotype, molecular, cytogenetics, and other techniques are used for its diagnosis.

Tags : Cancer, Non-Hodgkin’s Lymphoma, NHL, heterogeneous, malignant lymphomas, subtypes, morphology, immunophenotype, molecular, cytogenetics, diagnosis, Treatment, indolent, aggressive

Published on : Apr 28, 2021 | Views : 2106 | Downloads : 8

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Non-Hodgkin’s Lymphoma Luis Fayad, MD Assistant Professor Clinical Medical Director Lymphoma/Myeloma Department
Slide 2-

Non-Hodgkin’s Lymphoma Non-Hodgkin’s lymphomas (NHL) are a heterogeneous group of malignant lymphomas. There are many different subtypes, every few years the classification is updated. Today, morphology, immunophenotype, molecular, cytogenetics, and other techniques are used for diagnosis. Treatment generally depends on the aggressiveness of the disease (indolent, aggressive, or very aggressive) Current ICD-9-CM diagnosis code range 200.0_ – 200.8_ and 202.0_ – 202.9_
Slide 3-

Behavior Indolent – these lymphomas grow slowly. The majority of NHLs are considered indolent. Indolent lymphomas are generally considered incurable with chemotherapy and/or radiation therapy. Aggressive – these lymphomas have a rapid growth pattern. This is the second most common form of NHL and are curable with chemotherapy. Very Aggressive – these lymphomas grow very rapidly. They account for a small proportion of NHLs and can be treated with chemotherapy. Unless treated rapidly, these lymphomas can be life threatening.
Slide 4-

WHO/REAL Classification of Lymphoid Neoplasms B-Cell Neoplasms Precursor B-cell neoplasm Precursor B-lymphoblastic leukemia/lymphoma (precursor B-acute lymphoblastic leukemia) Mature (peripheral) B-neoplasms B-cell chronic lymphocytic leukemia / small lymphocytic lymphoma B-cell prolymphocytic leukemia Lymphoplasmacytic lymphoma‡ Splenic marginal zone B-cell lymphoma (+ villous lymphocytes)* Hairy cell leukemia Plasma cell myeloma/plasmacytoma Extranodal marginal zone B-cell lymphoma of MALT type Nodal marginal zone B-cell lymphoma (+ monocytoid B cells)* Follicular lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma Mediastinal large B-cell lymphoma Primary effusion lymphoma† Burkitt’s lymphoma/Burkitt cell leukemia§ T and NK-Cell Neoplasms Precursor T-cell neoplasm Precursor T-lymphoblastic leukemia/lymphoma (precursor T-acute lymphoblastic leukemia ‡ Formerly known as lymphoplasmacytoid lymphoma or immunocytoma II Entities formally grouped under the heading large granular lymphocyte leukemia of T- and NK-cell types * Provisional entities in the REAL classification Mature (peripheral) T neoplasms T-cell chronic lymphocytic leukemia / small lymphocytic lymphoma T-cell prolymphocytic leukemia T-cell granular lymphocytic leukemiaII Aggressive NK leukemia Adult T-cell lymphoma/leukemia (HTLV-1+) Extranodal NK/T-cell lymphoma, nasal type# Enteropathy-like T-cell lymphoma** Hepatosplenic γδ T-cell lymphoma* Subcutaneous panniculitis-like T-cell lymphoma* Mycosis fungoides/Sézary syndrome Anaplastic large cell lymphoma, T/null cell, primary cutaneous type Peripheral T-cell lymphoma, not otherwise characterized Angioimmunoblastic T-cell lymphoma Anaplastic large cell lymphoma, T/null cell, primary systemic type Hodgkin’s Lymphoma (Hodgkin’s Disease) Nodular lymphocyte predominance Hodgkin’s lymphoma Classic Hodgkin’s lymphoma Nodular sclerosis Hodgkin’s lymphoma (grades 1 and 2) Lymphocyte-rich classic Hodgkin’s lymphoma Mixed cellularity Hodgkin’s lymphoma Lymphocyte depletion Hodgkin’s lymphoma † Not described in REAL classification § Includes the so-called Burkitt-like lymphomas ** Formerly known as intestinal T-cell lymphoma # Formerly know as angiocentric lymphoma
Slide 5-

Indolent (35%) Diffuse large B-cell (31%) Armitage et al. J Clin Oncol. 1998;16:2780–2795. Mantle cell (6%) Peripheral T-cell (6%) Other subtypes with a frequency 2% (9%) Frequency of NHL Subtypes in Adults Composite lymphomas (13%)
Slide 6-

Marginal Zone Lymphoma Indolent Currently codes to 202.8_ Accounts for ~10% of all lymphomas Subcategories MALT (XRT?) Nodal Extra Nodal Splenic
Slide 7-

Mantle Cell Lymphoma Aggressive Currently codes to 202.8_ Accounts for ~ 6% of all lymphomas Considered “incurable” with traditional RX Stem cell transplant is offered often as front-line consolidation treatment in “younger” patients
Slide 8-

Primary CNS Lymphoma Aggressive Currently codes to 202.8_ Accounts for ~ 1-2% of all lymphomas Different chemotherapy treatments Often requires radiation to the brain: Brain dysfunction in younger patients Dementia in older patients
Slide 9-

Anaplastic Large Cell Lymphoma (ALCL) Aggressive Currently codes to 202.8_ Accounts for ~ 2% of all lymphomas Two groups: ALCL ALK-1+ better prognosis, more common in younger patients and children ALCL ALK-1-negative : as bad as any other T-cell lymphoma
Slide 10-

Peripheral T-cell Lymphoma Aggressive Currently codes to 202.8_ Accounts for ~ 7% of all lymphomas Worse prognosis, often associated with extranodal presentation Often requiring salvage treatment and transplant
Slide 11-

Large Cell Lymphoma Very Aggressive Currently codes to 200.0_ Accounts for ~ 31% of all lymphomas
Slide 12-

Other Recommendations Changes to terminology Changes in disease process
Slide 13-

Questions?